ECM
RARE icon

Element Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Element Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,348
Closed -$256K – 844
2018
Q3 		$256K Buy
+3,348
New +$272K 0.01% 653

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Element Capital Management's RARE Position: Q4 2018 in Review

Element Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 3,348 shares — an estimated $256K sold.

Element Capital Management first reported a position in RARE in Q3 2018 and held it in 1 quarter. The position peaked at $256K in Q3 2018. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

  • Element Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 3,348 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $256K.
  • Element Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and held it in 1 quarter.
  • Element Capital Management's Ultragenyx Pharmaceutical position peaked at $256K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.